Aktienanalyse zu Sutro Biopharma Inc (STRO)STROSutro Biopharma Inc

Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Sutro Biopharma Inc is currently a hold. The stock is trading at $9.11, significantly below its 52-week high of $43.85, indicating a potential for recovery. However, the RSI is at 26.36, suggesting it is oversold, and the forward P/E ratio is 10.03, indicating that while the stock may be undervalued, the company is still facing substantial financial losses, with a net income loss of $38.5 million reported in Q2 2026. The main risk is the declining revenue trend, with a 39.79% drop over the last 20 days, which raises concerns about the company's short-term performance.

4 analysts cover STRO: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 20.00.